19:02 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Aug. 7th. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill Lynch,...
03:27 , Aug 8, 2018 |  BC Extra  |  Financial News

Zogenix, Progenics raise follow-ons

Zogenix Inc. (NASDAQ:ZGNX) and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) each priced follow-on offerings late Tuesday. Zogenix raised $312 million through the sale of 6 million shares at $52 in an offering underwritten by BofA Merrill Lynch, Leerink,...
17:36 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Progenics' Azedra wins FDA nod for rare NETs

FDA approved Azedra iobenguane I 131 from Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) to treat unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. The agency said Azedra is the first drug it has approved for the rare...
20:29 , Jul 30, 2018 |  BC Extra  |  Company News

Progenics' Azedra wins FDA nod for rare NETs

FDA approved Azedra iobenguane I 131 from Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) to treat unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma. The agency said Azedra is the first drug it has approved for the rare...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
15:36 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

FDA extends review of Progenics' Azedra

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said FDA will extend its review of an NDA for Azedra iobenguane I 131, postponing its PDUFA date to July 30 from April 30. The therapy is under Priority Review to...
16:21 , Mar 23, 2018 |  BC Extra  |  Company News

FDA extends review of Progenics' Azedra

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) slipped $0.82 (10%) to $7.54 on Friday after it said FDA will extend its review of an NDA for Azedra iobenguane I 131, postponing its PDUFA date to July 30 from...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:12 , Jan 3, 2018 |  BC Week In Review  |  Clinical News

Progenics gets Priority Review for Azedra in rare NETs

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said FDA accepted and granted Priority Review to an NDA for Azedra iobenguane I 131 (Ultratrace I-131-MIBG, Ultratrace iobenguane I 131) to treat malignant recurrent and/or unresectable pheochromocytoma and paraganglioma. Its...
19:19 , Dec 29, 2017 |  BC Extra  |  Company News

Progenics' Azedra gets Priority Review for rare NETs

On Friday, Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said FDA accepted and granted Priority Review to an NDA for Azedra iobenguane I 131 (Ultratrace I-131-MIBG, Ultratrace iobenguane I 131) to treat malignant recurrent and/or unresectable pheochromocytoma and...